You are here: Industry Insights > AML

News List

Acute myeloid leukaemia market to reach $5.1 billion by 2029: GlobalData expresspharma
June 22, 2020
This growth will be driven by label expansions of the already successful drugs Venclexta, Tibsovo, Idhifa and Xospata, as well as by a strong late-stage pipeline.
AbbVie's Venclyxto shows promise as AML treatment pharmatimes
June 17, 2020
AbbVie has presented new data showing the potential of Venclyxto (venetoclax) to reduce the risk of death in previously untreated patients with acute myeloid leukaemia (AML) who were ineligible for intensive chemotherapy.
FDA accepts for priority review Bristol Myers Squibb’s application for CC-486 for maintenance treatm pharmaceutical-business-review
May 08, 2020
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for CC-486 for the maintenance treatment of adults in remission with acute myeloid leukemia (AML).
Ryvu Therapeutics Receives Orphan Drug Designation AML Treatment americanpharmaceuticalreview
April 01, 2020
Ryvu Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation (ODD) to Ryvu's SEL120, for the treatment of patients with acute myeloid leukemia (AML).
AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML pharmaceutical-business-review
March 27, 2020
AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA (venetoclax) in combination with azacitidine versus azacitidine in combination ...
Positive results announced for acute myeloid leukaemia treatment trial europeanpharmaceuticalreview
March 27, 2020
Positive topline results have been announced from a Phase II trial of VENCLEXTA® (venetoclax) in combination with azacitidine in patients with acute myeloid leukaemia (AML).
AbbVie Announces Positive Results from VENCLEXTA, Azacitidine Combination for AML americanpharmaceuticalreview
March 26, 2020
AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA® (venetoclax) in combination with azacitidine versus azacitidine in combination ...
Actinium Announces First Patient Treated in Acute Myeloid Leukemia Study americanpharmaceuticalreview
March 06, 2020
Actinium Pharmaceuticals announced the first patient has begun treatment in the third and final cohort of the Actimab-A CLAG-M combination trial.
Actinium Announces Actimab-A Plus 7+3 Combination Trial for AML americanpharmaceuticalreview
March 05, 2020
Actinium Pharmaceuticals is expanding its CD33 program studying Actimab-A into a combination trial with the chemotherapy regimen 7+3 in patients with newly diagnosed acute myeloid leukemia (AML) ...
VENCLEXTA, Low-Dose Cytarabine Combination Study for AML Does Not Meet Primary Endpoint americanpharmaceuticalreview
March 04, 2020
AbbVie announced the VIALE-C (M16-043) trial of venetoclax (VENCLEXTA®) in combination with low-dose cytarabine (LDAC) versus LDAC in combination with placebo did not meet its primary endpoint of ...

Previous page 1 2 3 4 5 6 7 8 9 10 Next page